comparemela.com

Hematology Adolescent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis Presents Updated Clinical and Translational Data

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company.

New yorkUnited statesFrance generalNorth carolinaPascalyne wilsonAshleyr robinsonNicolas boisselArthur strilAmerican society of hematologySecurities exchange commissionCellectis the company euronext growthEuropean hematology associationEuronext growthHematology adolescentYoung adult unitIntermediate dose level

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

NEW YORK, June 09, 2023 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated. | June 9, 2023

New yorkUnited statesFrance generalNorth carolinaNicolas boisselArthur strilAshleyr robinsonPascalyne wilsonAmerican society of hematologySecurities exchange commissionCellectis the company euronext growthEuropean hematology associationEuronext growthHematology adolescentYoung adult unitIntermediate dose level

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

New yorkUnited statesFrance generalNorth carolinaAshleyr robinsonNicolas boisselArthur strilPascalyne wilsonSecurities exchange commissionAmerican society of hematologyCellectis the company euronext growthEuropean hematology associationEuronext growthHematology adolescentYoung adult unitIntermediate dose level

vimarsana © 2020. All Rights Reserved.